Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

BACKGROUND: New therapeutic options for metastatic pancreatic cancer are urgently needed. In pancreatic cancer, overexpression of the epidermal growth factor receptor 2 (HER2) has been reported in up to 45%. This multicentre phase II study investigated the efficacy and toxicity of the HER2 antibody...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Harder, J, Ihorst, G, Heinemann, V, Hofheinz, R, Moehler, M, Buechler, P, Kloeppel, G, Röcken, C, Bitzer, M, Boeck, S, Endlicher, E, Reinacher-Schick, A, Schmoor, C, Geissler, M
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2012
Teme:
Clinical Study
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3304403/
https://ncbi.nlm.nih.gov/pubmed/22374460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.18
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki